Peripheral neuropathy in colorectal cancer survivors: The influence of oxaliplatin administration. Results from the population-based PROFILES registry

Antoinetta J. M. Beijers*, Floortje Mols, Vivianne C. G. Tjan-Heijnen, Catharina G. Faber, Lonneke V. van de Poll-Franse, Gerard Vreugdenhil

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

62 Citations (Web of Science)


Background. Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of oxaliplatin which can negatively influence quality of life. We aimed to study the influence of cumulative dose, dose schedule and dose reductions of adjuvant oxaliplatin on long-term severity and prevalence of CIPN among colorectal cancer (CRC) survivors. Material and methods. In total 207 patients, diagnosed with CRC between 2000 and 2009 who underwent adjuvant treatment with oxaliplatin, were included. They completed the EORTC QLQ-CIPN20 2-11 years after diagnosis. Data on oxaliplatin administration and acute neuropathy during treatment were extracted from the medical files. Subscales were analyzed with analysis of covariance and neuropathy symptoms with logistic regression analysis. Results. Patients who received cumulative oxaliplatin dose of >= 842 mg/m(2) had a significantly worse EORTC QLQ-CIPN20 sensory score compared to those who received a low cumulative dose of
Original languageEnglish
Pages (from-to)463-469
JournalActa Oncologica
Issue number4
Publication statusPublished - Apr 2015

Cite this